Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Retained Earnings (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Retained Earnings for 13 consecutive years, with -$561.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 277.18% year-over-year to -$561.7 million, compared with a TTM value of -$561.7 million through Dec 2025, down 277.18%, and an annual FY2025 reading of -$561.7 million, down 277.18% over the prior year.
  • Retained Earnings was -$561.7 million for Q4 2025 at Agios Pharmaceuticals, down from -$453.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $30.8 million in Q1 2021 and bottomed at -$1.0 billion in Q2 2024.
  • Average Retained Earnings over 5 years is -$429.5 million, with a median of -$439.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings skyrocketed 101.98% in 2021, then tumbled 1181.15% in 2022.
  • Year by year, Retained Earnings stood at -$238.8 million in 2021, then crashed by 97.09% to -$470.6 million in 2022, then crashed by 74.82% to -$822.6 million in 2023, then soared by 81.9% to -$148.9 million in 2024, then crashed by 277.18% to -$561.7 million in 2025.
  • Business Quant data shows Retained Earnings for AGIO at -$561.7 million in Q4 2025, -$453.7 million in Q3 2025, and -$350.2 million in Q2 2025.